vs

Side-by-side financial comparison of Repay Holdings Corp (RPAY) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $78.6M, roughly 1.6× Repay Holdings Corp). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 0.4%). Repay Holdings Corp produced more free cash flow last quarter ($23.2M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -1.3%).

Repay Holdings Corp is a leading payment technology provider delivering integrated end-to-end payment processing solutions for businesses across North America. Its offerings include credit/debit card processing, ACH transfer services, POS system integrations and digital payment tools, serving retail, healthcare, automotive and e-commerce segments to help clients streamline transaction workflows and boost operational efficiency.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

RPAY vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.6× larger
ZLAB
$127.1M
$78.6M
RPAY
Growing faster (revenue YoY)
ZLAB
ZLAB
+16.7% gap
ZLAB
17.1%
0.4%
RPAY
More free cash flow
RPAY
RPAY
$49.9M more FCF
RPAY
$23.2M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-1.3%
RPAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RPAY
RPAY
ZLAB
ZLAB
Revenue
$78.6M
$127.1M
Net Profit
$-140.1M
Gross Margin
74.2%
51.0%
Operating Margin
-182.2%
-54.6%
Net Margin
-178.3%
Revenue YoY
0.4%
17.1%
Net Profit YoY
-3304.1%
EPS (diluted)
$-1.68
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$78.6M
$127.1M
Q3 25
$77.7M
$115.4M
Q2 25
$75.6M
$109.1M
Q1 25
$77.3M
$105.7M
Q4 24
$78.3M
$108.5M
Q3 24
$79.1M
$101.8M
Q2 24
$74.9M
$100.1M
Q1 24
$80.7M
$87.1M
Net Profit
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$-140.1M
Q3 25
$-6.4M
$-36.0M
Q2 25
$-102.3M
$-40.7M
Q1 25
$-7.9M
$-48.4M
Q4 24
$-4.1M
Q3 24
$3.2M
$-41.7M
Q2 24
$-4.1M
$-80.3M
Q1 24
$-5.2M
$-53.5M
Gross Margin
RPAY
RPAY
ZLAB
ZLAB
Q4 25
74.2%
51.0%
Q3 25
74.4%
59.5%
Q2 25
75.7%
60.6%
Q1 25
75.9%
63.6%
Q4 24
76.3%
61.5%
Q3 24
77.8%
64.1%
Q2 24
78.2%
64.9%
Q1 24
76.2%
61.4%
Operating Margin
RPAY
RPAY
ZLAB
ZLAB
Q4 25
-182.2%
-54.6%
Q3 25
-3.9%
-42.3%
Q2 25
-138.7%
-50.3%
Q1 25
-4.7%
-53.3%
Q4 24
-1.5%
-62.6%
Q3 24
-0.9%
-66.6%
Q2 24
-4.6%
-76.0%
Q1 24
-3.1%
-80.7%
Net Margin
RPAY
RPAY
ZLAB
ZLAB
Q4 25
-178.3%
Q3 25
-8.3%
-31.2%
Q2 25
-135.2%
-37.3%
Q1 25
-10.3%
-45.8%
Q4 24
-5.3%
Q3 24
4.1%
-40.9%
Q2 24
-5.4%
-80.2%
Q1 24
-6.5%
-61.4%
EPS (diluted)
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$-1.68
$-0.05
Q3 25
$-0.08
$-0.03
Q2 25
$-1.15
$-0.04
Q1 25
$-0.09
$-0.04
Q4 24
$-0.04
$-0.09
Q3 24
$0.03
$-0.04
Q2 24
$-0.04
$-0.08
Q1 24
$-0.06
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPAY
RPAY
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$115.7M
$689.6M
Total DebtLower is stronger
$280.1M
Stockholders' EquityBook value
$484.4M
$715.5M
Total Assets
$1.2B
$1.2B
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$115.7M
$689.6M
Q3 25
$95.7M
$717.2M
Q2 25
$162.6M
$732.2M
Q1 25
$165.5M
$757.3M
Q4 24
$189.5M
$779.7M
Q3 24
$168.7M
$616.1M
Q2 24
$147.1M
$630.0M
Q1 24
$128.3M
$650.8M
Total Debt
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$280.1M
Q3 25
$279.5M
Q2 25
$279.0M
Q1 25
$497.6M
Q4 24
$496.8M
Q3 24
$496.2M
Q2 24
$435.6M
Q1 24
$434.9M
Stockholders' Equity
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$484.4M
$715.5M
Q3 25
$616.9M
$759.9M
Q2 25
$633.7M
$791.7M
Q1 25
$755.7M
$810.8M
Q4 24
$761.3M
$840.9M
Q3 24
$754.7M
$667.7M
Q2 24
$815.4M
$704.2M
Q1 24
$813.8M
$762.2M
Total Assets
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$1.2B
$1.2B
Q3 25
$1.3B
$1.2B
Q2 25
$1.4B
$1.2B
Q1 25
$1.5B
$1.2B
Q4 24
$1.6B
$1.2B
Q3 24
$1.6B
$985.3M
Q2 24
$1.5B
$987.4M
Q1 24
$1.5B
$988.4M
Debt / Equity
RPAY
RPAY
ZLAB
ZLAB
Q4 25
0.58×
Q3 25
0.45×
Q2 25
0.44×
Q1 25
0.66×
Q4 24
0.65×
Q3 24
0.66×
Q2 24
0.53×
Q1 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPAY
RPAY
ZLAB
ZLAB
Operating Cash FlowLast quarter
$23.3M
$-26.0M
Free Cash FlowOCF − Capex
$23.2M
$-26.7M
FCF MarginFCF / Revenue
29.6%
-21.0%
Capex IntensityCapex / Revenue
0.1%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$90.7M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$23.3M
$-26.0M
Q3 25
$32.2M
$-32.0M
Q2 25
$33.1M
$-31.0M
Q1 25
$2.5M
$-61.7M
Q4 24
$34.3M
$-55.8M
Q3 24
$60.1M
$-26.8M
Q2 24
$31.0M
$-42.2M
Q1 24
$24.8M
$-90.1M
Free Cash Flow
RPAY
RPAY
ZLAB
ZLAB
Q4 25
$23.2M
$-26.7M
Q3 25
$32.1M
$-35.0M
Q2 25
$33.0M
$-33.9M
Q1 25
$2.4M
$-63.2M
Q4 24
$34.0M
$-58.4M
Q3 24
$59.8M
$-28.2M
Q2 24
$30.5M
$-42.9M
Q1 24
$24.7M
$-91.1M
FCF Margin
RPAY
RPAY
ZLAB
ZLAB
Q4 25
29.6%
-21.0%
Q3 25
41.3%
-30.4%
Q2 25
43.6%
-31.1%
Q1 25
3.0%
-59.9%
Q4 24
43.5%
-53.8%
Q3 24
75.6%
-27.7%
Q2 24
40.7%
-42.9%
Q1 24
30.6%
-104.5%
Capex Intensity
RPAY
RPAY
ZLAB
ZLAB
Q4 25
0.1%
0.5%
Q3 25
0.2%
2.6%
Q2 25
0.1%
2.6%
Q1 25
0.2%
1.5%
Q4 24
0.3%
2.4%
Q3 24
0.3%
1.3%
Q2 24
0.6%
0.7%
Q1 24
0.1%
1.1%
Cash Conversion
RPAY
RPAY
ZLAB
ZLAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
18.52×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPAY
RPAY

Sales Channel Directly To Consumer$69.4M88%
Other$6.8M9%
Sales Channel Through Intermediary$2.3M3%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons